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Functional role of PGAM5 multimeric assemblies
and their polymerization into filaments
Karen Ruiz1, Tarjani M. Thaker1, Christopher Agnew1, Lakshmi Miller-Vedam2, Raphael Trenker1, Clara Herrera3,
Maria Ingaramo4, Daniel Toso5, Adam Frost 2,5,6 & Natalia Jura 1,7
PGAM5 is a mitochondrial protein phosphatase whose genetic ablation in mice results in
mitochondria-related disorders, including neurodegeneration. Functions of PGAM5 include
regulation of mitophagy, cell death, metabolism and aging. However, mechanisms regulating
PGAM5 activation and signaling are poorly understood. Using electron cryo-microscopy, we
show that PGAM5 forms dodecamers in solution. We also present a crystal structure of
PGAM5 that reveals the determinants of dodecamer formation. Furthermore, we observe
PGAM5 dodecamer assembly into filaments both in vitro and in cells. We find that PGAM5
oligomerization into a dodecamer is not only essential for catalytic activation, but this form
also plays a structural role on mitochondrial membranes, which is independent of phos-
phatase activity. Together, these findings suggest that modulation of the oligomerization of
PGAM5 may be a regulatory switch of potential therapeutic interest.
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Phosphoglycerate mutase family member 5 (PGAM5) is anatypical protein phosphatase implicated in a number offunctions within mitochondria, including organelle home-
ostasis, mitophagy, and cell death. As a member of the PGAM
histidine phosphatase superfamily, PGAM5 has the conserved
PGAM domain1. However, unlike most PGAM enzymes, which
are phosphotransferases or phosphohydrolases of small metabo-
lites, PGAM5 dephosphorylates protein substrates2, targeting
phosphorylated serine, threonine, and histidine residues3,4.
PGAM5 contains an N-terminal mitochondrial targeting
sequence (MTS), which also serves as a membrane anchor.
Experimental evidence supports PGAM5 localization to the outer
mitochondrial membrane (OMM), where its phosphatase domain
is accessible from the cytosol5 and to the inner mitochondrial
membrane (IMM)6,7. In response to loss of mitochondrial
membrane potential (ΔΨm)6 or apoptosis8,9, PGAM5 undergoes
cleavage by two IMM-resident proteases, presenilin-associated
rhomboid-like protein (PARL)6, and the metalloprotease
OMA110, generating a fragment of PGAM5 missing the MTS
(Fig. 1a) that can be partially released into the cytosol6,8,9,11.
Thus, the localization of PGAM5 seems dynamic and stress
responsive.
PGAM5 has been linked to mitochondrial homeostasis and cell
death through the regulation of mitochondrial dynamics,
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Fig. 1 Δ48 PGAM5 forms tubular filaments in solution composed of ring-like structures. a Domain architecture of constructs used in this study. Full-length
PGAM5 is comprised of a single transmembrane helix containing a mitochondrial targeting sequence (MTS), a linker domain including the regulatory
multimerization motif (MM), and a C-terminal PGAM phosphatase domain. The native cleavage site between residues 24 and 25, cleaved by PARL6, is
marked with a green arrow. b Elution profiles for Δ48 and Δ90 PGAM5 constructs purified by size exclusion chromatography (SEC) using a Superose 6
column (GE Healthcare) in SEC buffer containing 20mM Tris-Cl pH 8.0, 500 µM TCEP, and 150mM NaCl. The corresponding oligomeric states of each
peak observed in the chromatograms are indicated. c Representative EM micrographs of negatively stained protein samples taken from fractions
corresponding to the two distinct peaks observed in the Δ48 PGAM5 purification. d SEC profiles for Δ48 PGAM5 in SEC buffer and NaCl at a final
concentration of 150, 300, or 750mM. EM micrographs of negatively stained samples of Δ48 PGAM5 taken directly from the primary peak
obtained during purification are shown, highlighting the decomposition of filaments into rings at increasing salt concentrations. Scale bars in c and d
correspond to 50 nm, except for the inset in c in which the scale bar corresponds to 10 nm
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respiration and mitophagic quality control. Interaction partners
of PGAM5 include KEAP1, an adaptor protein for the Cul3-
dependent E3 ubiquitin ligase complex, and Bcl-XL, an anti-
apoptotic protein12. By inhibiting KEAP1 activity5, PGAM5
promotes retrograde transport of mitochondria along micro-
tubules by the GTPase Miro213. PGAM5 also regulates levels of
PTEN-induced kinase 1 (PINK1), a guardian of mitochondrial
quality control7,14, which upon mitochondrial damage accumu-
lates on the cytosolic surface of mitochondria to recruit Parkin
and initiate mitophagy15–18. In mice, PGAM5 stabilizes PINK1
and promotes mitophagy to protect against neuronal degenera-
tion7, whereas in flies PGAM5 negatively regulates PINK114. In
response to hypoxia or loss of mitochondrial membrane potential,
PGAM5 binds and dephosphorylates FUNDC1, promoting
recruitment of autophagosomes to mitochondria19, consistent
with PGAM5’s role in promotion of mitophagy. Notably, PGAM5
knockout in mice leads to a more severe Parkinson’s disease-like
phenotype than observed for PINK1 knockout, suggesting that
PGAM5 has multiple functions that support dopaminergic neu-
ron survival7,20–23.
The role of PGAM5 in cell death is poorly understood9,24,25. In
necroptosis, initiated by tumor necrosis factor alpha (TNFα),
PGAM5 may be a part of a complex with the kinases RIP1 and
RIP3 that promotes cell death through dephosphorylation of the
mitochondrial fission factor DRP124. However, the PGAM5/
DRP1 axis is dispensable for TNFα-induced necroptosis in many
cells and conditions26–29, except for ConA-induced hepatic
necrosis30. Other studies link PGAM5 to apoptosis through
sequestration of a caspase inhibitor, XIAP E3 ubiquitin ligase9.
During apoptosis, PGAM5 also contributes to mitochondrial
recruitment of Bax and to DRP1 dephosphorylation, possibly
by engaging them in a heteromeric complex31. Most recently,
PGAM5 was shown to protect cells from necroptosis through its
positive effect on PINK1-dependent mitophagy32.
Biochemical and structural studies elude to an elaborate
mechanism by which many functions of PGAM5 might be con-
trolled. Between the MTS and phosphatase domain, PGAM5
contains a linker domain (Fig. 1a) with a centrally located
“multimerization motif” that potentiates PGAM5 activity33. The
multimerization motif (MM) also promotes higher-order oligo-
merization of PGAM533. A crystal structure of PGAM5 con-
taining the linker and phosphatase domains showed that the MM
stabilizes a catalytically active conformation of the enzyme34. The
structure also revealed a dodecameric, ring-shaped organization
of the phosphatase domain in the crystal lattice34, of unknown
physiological relevance.
Here, we provide evidence that oligomerization is essential for
PGAM5 catalysis and present a new crystal structure of the
PGAM5 ring demonstrating the sufficiency of the MM for
PGAM5 dodecamer formation. We also discover that PGAM5
can adopt different oligomeric states in solution, including fila-
mentous structures composed of stacked dodecameric rings that
can form both in vitro and in cells. Lastly, we find that PGAM5
oligomerization exerts a structural effect on mitochondrial
membranes that is independent of its phosphatase activity. Taken
together, we propose that the functions of this atypical phos-
phatase are regulated through both catalytic and noncatalytic
mechanisms.
Results
Linker domain induces filamentation of the PGAM5 phos-
phatase. To understand the mechanism of oligomerization-
dependent activation of PGAM5, we purified a truncated form of
PGAM5 (Δ48 PGAM5), previously characterized as a stable and
fully active construct, which includes the MM (residues 58–63)
(Fig. 1a)33. We focused on the form of PGAM5, known as
PGAM5L, that has an intact PGAM domain formed by residues
98–289. Δ48 PGAM5 resolved as two distinct peaks during size
exclusion chromatography (SEC) (Fig. 1b). The later peak was
consistent with the profile expected for a dimeric complex of
PGAM5, similar to the elution observed for the isolated phos-
phatase domain (Δ90 PGAM5)33 (Fig. 1b). The earlier peak,
however, was consistent with a larger oligomer that has been
observed in biochemical preparations of a comparable construct,
Δ54 PGAM533,34.
Analysis of the chromatogram peaks using negative-stain
electron microscopy (EM) revealed the presence of spontaneously
formed filaments of several hundred nanometers in the earlier
peak. These filaments were not observed in purified samples of
PGAM5 dimers (Δ48 later peak or Δ90 PGAM5) (Fig. 1c).
Filaments were comprised of a repeating unit with an occasional
shift in register along the length of the filament. In addition,
singular ring-like particles frequently decorated the ends of the
filaments in an orientation perpendicular to the filament axis. We
hypothesized that the filaments are comprised of individual rings,
with the lumen of the ring forming the interior of the filament.
The lack of isolated rings within either sample suggests that
PGAM5 oligomerization into filaments is a cooperative process.
The presence of rings and their potential role as the building
blocks of PGAM5 filaments was intriguing, especially in light of a
recent crystal structure of Δ54 PGAM5, which revealed a ring-like
oligomer through lattice interactions between 12 copies of
PGAM5 (PDB: 5MUF)34. Δ48 PGAM5 filaments could be
dissociated into rings by increasing the ionic strength (Fig. 1d).
With high concentrations of NaCl (>500 mM NaCl), we could
enrich for discrete PGAM5 rings, enabling structural analyses on
the ring-like Δ48 PGAM5 state in solution.
PGAM5 rings in solution and in a new crystal structure. We
assessed the molecular structure of Δ48 PGAM5 rings in solution
by cryo-EM. Our data revealed a mixture of PGAM5 ring parti-
cles with dimensions consistent with the formation of single
rings, a doublet of rings, and less frequently, partial doublets
(Supplementary Figure 1). The particles adopted a preferred
orientation in the vitreous layer that limited the number of side
views necessary for complete 3D reconstruction. Thus, we per-
formed 2D classification of the top view of the Δ48 PGAM5 ring,
visualized along the central symmetry axis, revealing features of
PGAM5 at a resolution sufficient to analyze its organization
(Fig. 2a). The solution structure of Δ48 PGAM5 adopted
C6 symmetry in which six phosphatase domain dimers form a
ring. Comparison of the best 2D class of the Δ48 PGAM5 ring to
a projection image of the crystallographic ring observed in the
structure of Δ54 PGAM534 (filtered to the same 4.5 Å resolu-
tion as the 2D average) showed similar ring architectures
(Fig. 2b). Despite slightly different dimensions, stemming from
the crystallographic symmetry of the Δ54 PGAM5 structure
(Supplementary Figure 2a–d), the overall similarity in ring
architecture verified that the dodecameric assembly of PGAM5
observed in the crystalline lattice of Δ54 PGAM5 also occurs in
solution.
In the Δ54 PGAM5 crystal structure, the linker domain is
mostly disordered, except for a region corresponding to the
MM34. Similarly, we could not clearly identify the linker domain
in 2D classes of the Δ48 PGAM5 ring (Fig. 2a). These
observations suggested that the interactions supported by the
MM might be sufficient to drive oligomerization and activation of
PGAM5. This model is supported by a crystal structure we
determined for a shorter fragment of a catalytically dead PGAM5
phosphatase domain (Δ90 PGAM5 H105A), in complex with a
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peptide encompassing the MM (linker domain residues 54–67)
(Table 1, Fig. 2c). The asymmetric unit of the unit cell in our 2.6
Å resolution structure of Δ90 PGAM5 H105A/MM revealed
organization of the phosphatase domain into a dodecameric ring,
with the MM peptide positioned in the lumen of the ring at the
base of each phosphatase domain (Fig. 2c). Hence, our structure
demonstrates that the MM is sufficient to induce the formation of
a dodecameric PGAM5 ring, even when presented in trans.
The active conformation is independent of phosphate binding.
The dodecameric ring in the crystal structure of Δ90 PGAM5
H105A/MM has a central six-fold symmetry axis that better
matches the C6 symmetry of the 2D class of the Δ48 PGAM5 ring
than the C2 symmetry of the Δ54 PGAM5 crystallographic
dodecamer (Fig. 2b). The differences between the two ring geo-
metries stem from a slight rotation of the PGAM5 phosphatase
monomers at the α3 helical interface; whereas the dimer
interface-flanking residues F244 and burying approximately
1050.5 Å2 through hydrophobic interactions is the same in both
structures (Supplementary Figure 2e). Despite the differences, the
ordered β3–α3 catalytic loop (residues 172–193) indicated that
the phosphatase domain in both structures is in the active con-
formation (Fig. 3a). A notable difference between the Δ54
PGAM5 structure and the Δ90 PGAM5 H105A/MM structure
occurred in the β1–α1 loop (residues 105–121). In the Δ54
PGAM5 structure, this loop is ordered, whereas it is missing in
the Δ90 PGAM5 H105A/MM dodecamer. This difference could
be due to the engagement of the β1–α1 loop in crystal contacts in
the Δ54 PGAM5 structure, but not in the Δ90 PGAM5 H105A/
MM structure.
Mutation of the catalytic histidine (H105) to alanine resulted in
active-site arrangements in our ring structure of Δ90 PGAM5
resembling an active state described as the PO4 “on” conforma-
tion in the Δ54 PGAM5 structure34 (Fig. 3b, left and right
panels). In this on state, the H230 residue is positioned inward
relative to its position in the structure of the inactive phosphatase
domain alone (Δ90 PGAM5 (PDB:3MXO); Fig. 3b, center panel).
In the Δ54 PGAM5 structure residue R152 adopts a vertical,
rather than the planar position observed in the Δ90 PGAM5
dimer structure34, forming cation-π–stacking interactions with
Y108, and together with H230 and H105, coordinates an active-
site phosphate (Fig. 3b, right panel). In the Δ90 PGAM5 H105A/
MM structure, residues R152, Y108, and H230 adopt similar
orientations, but in the absence of phosphate (Fig. 3b, left panel).
The on state observed for Δ90 PGAM5 H105A/MM in the
absence of bound phosphate underscores the importance of ring
assembly for stabilizing the active architecture of the catalytic site.
Chaikuad et al.34 suggested that capping of the active site by
the β3–α3 loop positions active-site residues in the catalytically
competent state. However, a crystal structure of Δ90 PGAM5
a c Δ90 PGAM5 H105A/MM
139Å
~65Å
~40Å
Monomer 1
Outer ring
Monomer 2
Lumen
Multimerization motif 2
Multimerization motif 1
Δ48 PGAM5
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Fig. 2 Architecture of the PGAM5 dodecameric ring in solution and in a new crystal structure. a 2D class average of the predominant view of the ring
assembly observed in cryo-EM micrographs of Δ48 PGAM5 reveals a dodecameric topology highly similar in architecture to b. b 2D projection image of
the crystallographic ring observed in the crystal lattice of Δ54 PGAM5 (PDB: 5MUF) limited to 4.5 Å resolution. c Architecture and subunit arrangement of
the dodecameric assembly observed in the crystal structure of the Δ90 PGAM5 H105A phosphatase domain crystallized in the presence of a peptide
containing the multimerization motif (MM)
Table 1 Data collection and refinement statistics
Δ90 PGAM5 H105A/
MM
Δ90 PGAM5
H105A
Data collection
PDB ID 6CNL 6CNI
Space group P 21 21 21 P 21 21 21
Cell dimensions
a, b, c (Å) 49.4, 242.5, 272.5 71.0, 72.0, 81.9
α, β, γ (°) 90, 90, 90 90, 90, 90
Resolution (Å) 48.6 – 2.6 (2.69 – 2.6) 41.0–1.7 (1.76 – 1.7)
Rsym or Rmerge 19.8 (105.8) 7.5 (76.0)
I/σI 7.2 (1.4) 21.8 (2.3)
Completeness (%) 99.8 (99.9) 99.7 (97.5)
Redundancy 5.0 (5.1) 12.1 (7.8)
Refinement
Resolution (Å) 48.6–2.6 (2.69–2.6) 41.0–1.7 (1.76–1.7)
No. of reflections 509,660 (51,383) 564,588 (35,185)
Rwork/Rfree, % 22.3/26.4 (30.9/33.6) 17.1/19.7 (25.9/31.3)
No. of atoms
Protein 18,643 2893
Ligand/ion 31 16
Water 199 308
B-factors
Protein 35.5 26.2
Ligand/ion 30.5 25.8
Water 31.8 37.4
R.M.S. deviations
Bond lengths (Å) 0.004 0.007
Bond angles (°) 0.8 1.1
Ramachandran plot, %
Favored 97.8 99.4
Additional allowed 2.2 0.00
Values in parentheses are for highest-resolution shell
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H105A without the MM that we determined suggests otherwise
(Table 1, Supplementary Figure 3). In this structure, PGAM5
phosphatase formed a dimer analogous to the one previously
observed in the structure of Δ90 PGAM5 wild type (PDB:3MXO).
Although the crystal packing is identical in the two Δ90
PGAM5 structures, the active-site residues of Δ90 PGAM5
H105A adopt catalytically competent conformations (PO4 “on”)
in the presence of a phosphate ion (Supplementary Figure 3b).
The main difference between this dimer conformation and the
apo “on” state of the dodecameric Δ90 PGAM5 H105A/MM
structure is a disordered β3–α3 loop in Δ90 PGAM5 H105A.
Thus, in the absence of discrete phosphatase domain interactions
with the β3–α3 loop, the active architecture can be achieved, at
least structurally, as long as a phosphate ion is coordinated.
Altogether, these structures point to a remarkable plasticity of the
PGAM5 catalytic center, which indicates that multiple structural
elements coordinate for catalysis.
We also observed a notable difference in the conformation of
the C-terminal region of the MM between our Δ90 PGAM5
H105A/MM structure and the previously determined Δ54
PGAM5 structure34. Although an identical length of the linker
is resolved in both, the improved resolution of the Δ90 PGAM5
H105A/MM structure and overall quality of the electron density
map in the linker region revealed a register shift in which the
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Fig. 3 Key features of PGAM5 activation in the crystal structure of Δ90 PGAM5 H015A/MM. a The structures of Δ90 PGAM5 H105A with the
multimerization motif (MM) added in trans (Δ90 PGAM5 H105A/MM) (left panel) compared to the structures of Δ90 PGAM5 (PDB: 3MXO) (middle
panel) and Δ54 PGAM5 with the MM present in cis (PDB: 5MUF) (right panel). Monomers 1 and 2 are colored cyan and light blue, respectively, in all
structures with their corresponding MM regions colored in teal (monomer 1 MM) and dark blue (monomer 2 MM) where present. The β1–α1 loop is
indicated in orange, the β3–α3 loop is indicated in green, the α3–β4 loop is indicated in red. The F244 residues in the central axis forming the dimer
interface are indicated in yellow. b Detailed view of the catalytic core in Δ90 PGAM5 H105A/MM (left), Δ90 PGAM5 (middle), and Δ54 PGAM5 (right)
highlighting interactions between active-site residues and the phosphate ion (PO4). c, d Comparison of the MM architecture (left panel) and the
differences in interactions with the phosphatase domain (right panel) for c Δ90 PGAM5 H105A/MM and d Δ54 PGAM5
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positions of R64 and R65 in the Δ54 PGAM5 structure are
occupied by R65 and E66 in the Δ90 PGAM5 H105A/MM
structure, respectively (Fig. 3c, d; Supplementary Figures 2e, 4). In
Δ90 PGAM5 H105A/MM, R64 is positioned directly in the center
of a dimerization interface mediated by the α3 helices (Fig. 3c,
right panel), expanding the network of interactions in this region.
The guanidinium group of R64 in monomer 1 is also involved in
a previously unobserved cation π-stacking interaction in trans
with the phenyl ring of Y198 of the adjacent monomer. Residue
E199, previously described as hydrogen bonded to R64 of the
adjacent monomer, now interacts with R65. In both structures,
R214 hydrogen bonds in cis with D63, and R209 with the
backbone carbonyl of Y198 in trans (Fig. 3c, d).
Catalytic activation of PGAM5 requires dodecamer formation.
We further examined the role of dodecamer formation in the
regulation of PGAM5 activity. In PGAM5 ring structures, each
MM peptide interacts with three phosphatase domain monomers.
An interaction with the central phosphatase subunit involves
binding of the WDxxWD sequence of the MM. Two additional
minor interactions engage N- and C-terminal ends of the MM
with two distinct dimer interfaces formed by the neighboring
phosphatase domains (Fig. 4a). We defined the first minor
interaction as the F dimer interface because of the presence of a
pair of centrally located F244 residues supporting the dimeriza-
tion interface. We defined the second interaction as the α3 dimer
interface, because it involves a phosphatase domain dimer that
d
c
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Fig. 4 PGAM5 multimerization is required for catalysis. a Overview of interactions contributing to the stability of the dodecamer assembly in the structure
of Δ90 PGAM5 H105A/MM. b SEC elution profiles of wild type (WT) and interface-disrupting mutants (R65A, H105A, Y198E, F244E, and A4) of Δ48
PGAM5 in 150mM NaCl-containing buffer, highlighting the effect of the MM (R65A, A4), and dimer interface (F244E, Y198E) mutants on the oligomer/
dimer equilibria observed for wild-type Δ48 PGAM5. c EM micrographs of negatively stained samples of interface mutants of PGAM5 corresponding to the
oligomer peaks for WT and H105A, and dimer/monomer peaks for all the other mutants as shown in b. The insets in top right corners illustrate the position
of the respective mutations within the PGAM5 dodecamer cartoon. Scale bars correspond to 50 nm. d Phosphatase activity of the WT and mutant variants
of Δ48 PGAM5 measured for 20 nM enzyme and varying concentrations of a phosphorylated ASK1 substrate peptide. Data are represented as mean ± S.E.
M. The kinetic parameters Km, kcat, and kcat/Km were determined using GraphPad Prism and are summarized in Table 2
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engages the α3 helices. We introduced the F244E mutation to
disrupt the F dimer interface and Y198E or R65A mutations to
disrupt the α3 dimer interface (Fig. 4b). We also generated an A4
mutant of PGAM5 in which residues WDxxWD of the MM are
replaced by the AAxxAA sequence, which inactivates PGAM533.
All four mutations affected Δ48 PGAM5 oligomerization
(Fig. 4b, c). The F244E mutation had the most dramatic effect,
shifting the entire population of Δ48 PGAM5 to a monomeric
state. Likewise, the A4 mutant did not engage in higher-order
oligomerization and, instead, preferentially formed dimers. Like
the A4 mutant, both the Y198E and R65A mutants were
predominantly or completely dimers. Because none of the A4,
Y198E, or R65A mutations altered the F dimer interface, we
predicted that their dimeric state is likely stabilized by the F244-
centered interface (Fig. 4a). These findings suggested that,
although both the F dimer and α3 dimer interfaces are important
for ring formation, only the F244-mediated dimerization occurs
in the absence of dodecamer formation.
We determined the catalytic activity of the PGAM5 interface
mutants, including the H105A and A4 mutants as negative
controls, by measuring the rate of PGAM5-mediated depho-
sphorylation of a phospho-ASK1 substrate peptide (Table 2). The
monomerizing F244E mutation resulted in complete loss of
phosphatase activity (Fig. 4d). The Y198E and R65A mutations,
which dissociated Δ48 PGAM5 ring oligomers without disrupting
the F dimer, also impaired phosphatase activity, decreasing
catalytic efficiency ~two and ~fivefold, respectively (Fig. 4d,
Table 2). The negative effect of every mutation disrupting
PGAM5 ring assembly on phosphatase activity indicated that
dodecamer formation is necessary to achieve maximal catalytic
efficiency. These results also showed that phosphatase activity
primarily depends on the interaction between the MM and
phosphatase domains through the F dimer interface and that
organization of F dimers into a hexameric ring through the α3
dimer interface further potentiates activity.
Filament formation does not enhance PGAM5 activity. In
solutions of physiological ionic strength, Δ48 PGAM5 existed
predominantly as filaments composed of repeating dodecameric
rings (Fig. 1c). Although such structures are not present in the
crystal lattice of Δ54 PGAM534, the unit cell of our Δ90 PGAM5
H105A/MM structure reveals rings stacked to form tubular fila-
ments (Fig. 5a). Within the filament, each successive ring is
rotated ~15° around the 6-fold symmetry axis relative to the
neighboring ring. This architecture resembles the filament orga-
nization of Δ48 PGAM5 examined by negative-stain EM
(Fig. 5b). In the crystal structure, the lattice interactions that
mediate ring stacking lack an extensive buried surface area and
rely on sparse and nonsymmetrically distributed hydrogen bond
interactions between residues within loops at the perimeter of the
rings (Fig. 5c and Supplementary Figure 5a). This could explain
the apparent lack of structural rigidity in the EM images (Fig. 5b).
Mutation of the hydrogen-bonding residues did not have a
measurable effect on formation of the Δ48 PGAM5 filaments in
solution (Supplementary Figure 5b), suggesting that stabilization
of filament formation likely occurs through forces independent of
loop interactions observed in the crystal structure.
The twofold rotational symmetry relating individual mono-
mers within each phosphatase dimer results in identical
electrostatic surface potentials on both sides of the dodecameric
assembly (Fig. 5d). Basic residues comprise a large positively
charged patch centered on the catalytic clefts of each dimer
surrounded by somewhat negatively charged protruding loops.
The structural and electrostatic symmetry suggests that filament
formation lacks directionality and can occur from either face of
the ring. These characteristics, together with the disruptive effect
of high-ionic strength on PGAM5 filaments (Fig. 1d), implicate
complementary electrostatic forces in stabilizing the formation of
PGAM5 filaments in vitro. To test this, we designed two charge-
reversing mutations within the basic cleft, R269E and R288E, and
examined their influence on PGAM5 filamentation. In buffers
with physiological salt concentrations, each mutation reduced
PGAM5 filament length and formation, with the R288E mutation
having the greater effect (Fig. 5e). With the R288E mutant, we
then investigated the role filaments play in regulating phospha-
tase activity. The phosphatase activities were similar for both wild
type and R288E Δ48 PGAM5, suggesting that filament formation
does not contribute substantially to the catalytic efficiency of
PGAM5 phosphatase activity (Fig. 5f, Table 2).
PGAM5 forms large oligomers in cells upon cleavage from
IMM. We investigated whether PGAM5 also organizes into fila-
ments in living cells. Our biochemical and structural analysis of
the filaments focused on PGAM5 without its membrane-
anchoring helix. This construct approximates the state of
PGAM5 generated by PARL or OMA1 cleavage in response to the
loss of mitochondrial membrane potential upon treatment with
CCCP, a small molecule inhibitor of oxidative phosphorylation.
The resulting cleaved PGAM5 is mainly detected in mitochon-
dria, with only a fraction detectable in the cytosol6,8,9,11. We
explored the subcellular localization and oligomerization of
endogenous PGAM5, using CCCP to induce cleavage of PGAM5
in HEK293T cells and subcellular fractionation to distinguish
between the cytoplasmic and mitochondrial pools of PGAM5. In
CCCP-treated cells, cleaved PGAM5 predominantly partitioned
to mitochondria (Fig. 6a). To assess the oligomeric state of
mitochondrial PGAM5 before and after cleavage, we used blue
native electrophoresis (BN-PAGE). We confirmed that BN-PAGE
could differentiate different sizes of PGAM5 oligomers by com-
paring the migration of recombinant wild type Δ48 PGAM5 and
the oligomerization-deficient mutant F244E (Fig. 6b). By com-
paring the migration of endogenous PGAM5 in the cytoplasmic
(cyto) and mitochondrial (mito) fractions of untreated or CCCP-
treated cells, we observed markedly higher molecular weight
species for the cleaved pool of mitochondrial PGAM5 compared
to the uncleaved population, approximating the behavior of the
recombinant wild-type Δ48 PGAM5 filaments (Fig. 6b). We
observed a similar pattern in the cytosolic fraction after CCCP
treatment, although the cytosolic pool represented only a small
fraction of the total PGAM5 detected.
Table 2 Phosphatase activity of PGAM5 and its
oligomerization-deficient mutants
Protein Km (µM) Kcat (min−1) Kcat/Km (min−1 M−1)
Δ48 WT 115.2 ± 5.0 137.20 ± 2.98 1.19 (±0.06) × 106
Δ48 H105A ND ND ND
Δ48 R288E 174.70 ± 26.99 143.30 ± 12.73 0.82 (± 0.15) × 106
Δ48 F244E ND ND ND
Δ48 A4 ND ND ND
Δ48 R65A 119.9 ± 15.7 23.17 ± 1.55 0.19 (±0.03) × 106
Δ48 Y198E 86.17 ± 6.19 51.65 ± 1.68 0.60 (±0.05) × 106
Dephosphorylation of the ASK1 phosphopeptide by WT and mutant variants of Δ48 PGAM5 was
measured at 20 nM of enzyme concentration and varying concentrations of ASK1 substrate. The
kinetic parameters Km, kcat, and kcat/Km were determined using GraphPad Prism software. Kinetic
data for PGAM5 variants without measurable phosphatase activity are denoted ND (not
determined). Data are represented as mean ± S.E.M.
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To visualize PGAM5 filaments in cells, we focused on cytosolic
cleaved PGAM5 due to resolution limits preventing the
distinction between membrane-tethered and cleaved PGAM5
molecules in the mitochondrial intermembrane compartment. To
increase the pool of the cleaved cytosolic PGAM5, we expressed
and imaged myc-tagged Δ23 PGAM5 (residues 24–289),
mimicking the cleaved version, in COS7 cells using confocal
microscopy. In a small subset of transfected cells, we observed
myc-positive wire-like cytosolic structures (Fig. 6c). Using two
higher-resolution imaging techniques, stimulated emission deple-
tion microscopy (STED) and structured illumination microscopy
(SIM), we visualized PGAM5 filaments throughout the cytoplasm
in the subset of cells with this PGAM5 phenotype (Fig. 6c). As a
control, we evaluated the PGAM5 phenotype of the filament
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disrupting mutant, R288E (Fig. 5e). We did not find any cytosolic
filaments in cells expressing the R288E mutant of Δ23 PGAM5
(Fig. 6d). All mutations that disrupted dodecamer assembly and
consequently formation of PGAM5 filaments in vitro (Fig. 4b, c)
also eliminated the detection of filaments in cells (Supplementary
Figure 7). Thus, the cellular structures we observed have
properties like the PGAM5 filaments observed in vitro.
We noted that the architecture of cleaved PGAM5 filaments
formed in cells resemble cytoskeletal structures. To test for a
spatial relationship between PGAM5 filaments and cytoskeleton,
we assessed PGAM5 filament colocalization with actin fibers or
microtubules. Although we did not detect overlap between
PGAM5 filaments and actin fibers (Supplementary Figure 8a),
PGAM5 filaments colocalized with microtubules (Supplementary
Figure 8b). Upon nocodazole treatment to disrupt microtubule
polymerization, detection of PGAM5 filaments was lost (Supple-
mentary Figure 9), suggesting a potentially intriguing dependence
of PGAM5 filament assembly in cells on PGAM5 association with
intact microtubules.
PGAM5 dodecamers promote mitochondrial clustering. Under
conditions of intact mitochondrial membrane potential, PGAM5
is expected to remain in the uncleaved, membrane-tethered form.
To examine the importance of PGAM5 oligomerization in this
context, we leveraged the observation that overexpression of full-
length PGAM5 induced clustering of mitochondria in the peri-
nuclear region5. PGAM5 knockdown has an opposite effect on
mitochondria, resulting in increased tubular morphology26 and
decreased stress-induced mitochondrial clustering35. Such effects
on mitochondrial behavior stemming from changes in PGAM5
abundance may reflect the role of PGAM5 in maintaining
mitochondrial homeostasis13,26,33. Using confocal imaging of
COS7 cells, we evaluated the colocalization of full-length PGAM5
or PGAM5 mutants and a marker of mitochondrial outer
membranes, Tom20, and assessed the effect of full-length
PGAM5 expression on mitochondrial morphology (Fig. 7a).
Consistent with previous reports33, expression of the two cata-
lytically inactive PGAM5 mutants, H105A and A4, had opposing
effects on mitochondrial clustering. The membrane-tethered
H105A mutant induced mitochondrial clustering, similar to the
effect of overexpressing wild type PGAM5; the A4 mutant
resulted in fragmentation of the mitochondria (Fig. 7a, b).
The differences in the architecture of recombinant PGAM5
complexes formed by the H105A and A4 mutants could explain
their effects on mitochondria. Although both mutations inactivate
PGAM5, the H105A mutant can still form higher-order
oligomers whereas the A4 mutant prevents multimerization
(Fig. 4b, c). Thus, we hypothesized that the assembly of the
PGAM5 dodecamer, and perhaps also filamentation, drives
changes in mitochondrial morphology. To test this hypothesis,
we expressed the F244E mutant, which disrupts the F dimer
interface and prevents multimerization, and observed that it
failed to induce mitochondria clustering. Instead, the F244E
mutant caused mitochondrial fragmentation similar to the A4
mutant (Fig. 7a, b). Expression of both α3 dimer interface
mutants (Y198E and R65A), which disrupt ring and filament
formation but preserve some phosphatase activity, also failed to
induce mitochondrial clustering and resulted in a more tubular
phenotype than the A4 or F244E mutants. These results suggested
that mitochondrial-clustering phenotype depends on intact
dodecamer interfaces of PGAM5, independent from its activity.
To evaluate if assembly of PGAM5 dodecamers into filaments
affects mitochondrial clustering, we evaluated the R288E muta-
tion, which disrupted formation of PGAM5 filaments in vitro
without affecting the structure of the PGAM5 dodecamer
(Fig. 5e). Expression of the R288E mutant induced mitochondrial
clustering, suggesting that filament formation is either nones-
sential for mitochondrial clustering or is precluded when PGAM5
is embedded within mitochondrial membranes (Fig. 7a, b).
Mitochondrial clustering by PGAM5 is independent of DRP1.
DRP1, a cytosolic dynamin-family GTPase that binds to its
receptors on the OMM to promote mitochondrial fission36, is a
substrate of PGAM524,33. We investigated if the clustering effect
of PGAM5 overexpression on mitochondrial morphology
depends on DRP1 by assessing mitochondrial morphology in
Drp1−/− mouse embryonic fibroblasts (MEFs) upon PGAM5
overexpression. The smaller size of MEF cells relative to COS7
cells made it difficult to categorize the full spectrum of pheno-
types noted for COS7 cells (Fig. 7a, b), thus we limited the
phenotypic analysis of MEFs to three categories: (i) tubular/
elongated, (ii) fragmented, and (iii) aggregated (Supplementary
Figure 10). In untransfected Drp1−/− cells, mitochondrial tubules
were more connected and elongated37–39 than in wild-type MEFs
(Supplementary Figure 11a); however, we were still able to
identify all three mitochondrial phenotypes (Supplementary
Figure 10). The distribution of phenotypes was comparable to
that in wild type MEFs, despite differences in the overall
appearance of the mitochondrial tubules (Supplementary
Figure 11b).
Overexpression of wild-type PGAM5 in wild-type or Drp1−/−
MEFs resulted in mitochondrial clustering similar to that
observed in COS7 cells (Supplementary Figure 11b, c). Expression
of F244E PGAM5 in either wild type or DRP1-knockout cells
resulted in a shift to the fragmented phenotype of mitochondria
(Supplementary Figure 11b, c). Thus, the effects of PGAM5
overexpression on mitochondrial phenotypes are independent of
DRP1.
Fig. 5 Role of PGAM5 filaments in catalysis. a, b Overview of the a crystal packing in the Δ90 PGAM5 H105A/MM structure (left panel) highlighting a
network of stacked rings (right panel), which resembles the organization of b filaments observed for Δ48 PGAM5 in solution by negative-stain EM.
c Overview of the ring stacking interface highlighting the positions of residues at the surface of the substrate-binding cleft relative to structural elements
contributing to peripheral interactions between two adjacent dodecamers within the crystal lattice of the Δ90 PGAM5 H105A/MM structure.
d Electrostatic surface potential calculated for the Δ90 PGAM5 H105A/MM dodecamer using APBS71. The positions of the MM outlined in green are
shown relative to the positions of basic residues R269E and R288E within the positively charged substrate-binding cleft as well as the catalytic residue,
H105, in the active site. Coloring corresponds to the electronegativity of the surface potential as defined in the scale bar, with more negatively charged
surfaces colored red and positively charged surfaces colored blue. e Upper panel: size exclusion chromatograms of the WT Δ48 PGAM5 purified in buffer
containing low (150mM NaCl) or high (750mM NaCl) salt concentrations compared to the results obtained for the R269E and R288E variants. Lower
panel: EM micrographs of the negatively stained samples of mutant Δ48 PGAM5 taken from the corresponding primary peak of the purification.
f Phosphatase activity of the wild type (WT), catalytically inactive H105A, and the stacking-impaired R288E variants of Δ48 PGAM5 measured for 20 nM
enzyme and varying concentrations of a phosphorylated ASK1 substrate peptide. Data are represented as mean ± S.E.M. The kinetic parameters Km, kcat,
and kcat/Km were determined using GraphPad Prism and are summarized in Table 2. Scale bars in b and e correspond to 50 nm, except for the inset in b in
which the scale bar corresponds to 10 nm
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PGAM5 localizes at contact sites of clustered mitochondria. To
characterize the spatial distribution of wild type and F244E
PGAM5 at the mitochondria, we used STED to visualize the
OMM with Tom20 immunostaining or the IMM with
Tim23 immunostaining. In untransfected COS7 cells, mito-
chondria adopted a phenotype in which tubular Tom20-positive
or Tim23-positive structures extended radially from the peri-
nuclear regions (Fig. 8a). In cells transiently transfected with
wild-type PGAM5, mitochondrial tubules were replaced by cir-
cular mitochondria clustered in the perinuclear region (Fig. 8b).
Frequently, single clusters were found stacked next to each,
appearing as though these membranes were in direct contact
(Fig. 8c). PGAM5 was localized exclusively inside of these dis-
torted mitochondrial structures and detected as puncta that
mostly colocalized with Tim23 and not with Tom20 (Fig. 8b, c).
We also observed that PGAM5 colocalization with Tom20 only
occurred at the sites of contact between individual mitochondrial
clusters (Fig. 8b, c).
As with confocal analysis (Fig. 7a), STED imaging showed that
F244E PGAM5 expression resulted in a fragmented mitochon-
drial morphology and more diffuse distribution of mitochondrial
vesicles in the cell (Fig. 8b). In contrast to wild type PGAM5, the
F244E-positive mitochondria did not engage in any apparent
intermitochondrial contacts and PGAM5 in these cells was not
colocalized with Tom20. Rather, the F244E mutant was primarily
found in Tim23-positive structures (Fig. 8b, c). These data point
to a functional importance of PGAM5 multimerization in
bridging adjacent mitochondrial membranes to promote interac-
tions that might underlie the clustered phenotype. Our data are
also consistent with a localization for PGAM5 at the inner
mitochondrial membrane and/or possibly also within the
intermembrane space, as evidenced by partitioning of the
PGAM5 signal at the inner periphery of the OMM and
colocalization with Tim23.
Discussion
Here, we investigated activation mechanisms of the PGAM5
phosphatase, whose remarkable spectrum of functions in mito-
chondria parallels the pleiotropic roles of the organelle itself. We
discovered that PGAM5 assembles into symmetric rings in
solution that polymerize into filaments. We showed that the ring
structure, first observed by Chaikuad et al.34 for a PGAM5 con-
struct containing its linker and phosphatase domains, also forms
when phosphatase domain without these additional contiguous
regions is crystallized in the presence of a peptide encompassing
only the multimerization motif (MM). Observation of PGAM5
rings in solution indicates that this form is an energetically
favored state of the PGAM5 phosphatase.
Our studies demonstrate that the assembly into the dodeca-
meric ring is an essential determinant of efficient catalytic acti-
vation of PGAM5. The multimerization step is critical: the
interaction between a MM within the linker domain and a pair of
phosphatase domains is essential for stabilization of the phos-
phatase in the active state. This interaction is further stabilized by
neighboring subunits in the oligomer. The linker domain of
PGAM5 mediates several protein–protein interactions, such as
binding of KEAP1 and XIAP ubiquitin ligases5,9 and Bcl-XL12. It
is possible that through such interactions, the linker domain may
regulate oligomerization, further tuned by possible post-
translational modifications within the linker region. The
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Fig. 6 Cleaved PGAM5 forms oligomers in cells. a SDS-PAGE analysis of endogenous PGAM5 in HEK293T whole cell lysate (WCL), mitochondrial (mito),
and cytoplasmic (cyto) fractions 4 h post-CCCP treatment. Uncleaved (UC) and cleaved (C) PGAM5 bands are marked by arrows. b BN-PAGE analysis of
endogenous PGAM5 4 h post-CCCP treatment in mitochondrial (mito) and cytoplasmic (cyto) fractions. Fractionation samples were normalized based on
the total protein concentrations determined for the WCL samples. As a reference for migration behavior of PGAM5 oligomers, recombinant Δ48WT (Δ48
WT) and the oligomerization-deficient mutant Δ48 F244E mutant (Δ48 F244E) PGAM5 were run alongside cellular fractionation samples on a 4–16%
native-PAGE acrylamide gel (Invitrogen). Following electrophoresis, gels were immunoblotted with anti-PGAM5 antibody. c Comparison of myc-tagged
Δ23 PGAM5 filaments in transiently transfected COS7 cells stained with anti-myc antibody using three different imaging methods: confocal microscopy
(left panel), stimulated emission depletion (STED) microscopy (middle panel), and structured illumination microscopy (SIM) (right panel). All scale bars
correspond to 5 µm. d SIM images of myc-tagged Δ23 PGAM5 filaments in COS7 cells transiently expressing wild type (WT) or the R288E PGAM5 (red).
Nuclei were stained using DAPI (blue). Both scale bars in d correspond to 10 µm
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sufficiency of the presentation of the MM in trans could
also create a mechanism for propagation of regulatory mod-
ifications from one PGAM5 monomer to another, or even
between dodecamers, if PGAM5 subunits in the oligomers are
capable of exchanging. This could equip PGAM5 with the ability
to store information, such as the status of phosphatase domain
activation, in a manner analogous to that described for CamKII40.
The multimeric organization of PGAM5 might also have
important implications for its substrate specificity as a phos-
phatase. Some PGAM5 substrates form higher-order oligomeric
structures, including DRP1, which self-assembles into rings or
filaments36,41. GTP hydrolysis, an important step in mitochon-
drial constriction by DRP1, is thought to release DRP1 from its
mitochondrial receptors and triggers DRP1 filaments to curl into
ring-shaped oligomers, often dodecamers41, analogous to the
PGAM5 oligomers that we describe here. Although DRP1
associates with the OMM and PGAM5 resides primarily in IMM,
we observed that PGAM5 colocalizes with the OMM marker at
contact sites between two adjacent mitochondrial vesicles within
the mitochondrial clusters promoted by PGAM5 overexpression.
These PGAM5-enriched contact sites may represent a type of
membrane fusion or fission intermediate involving the formation
of local membrane pores42–47, which could facilitate interactions
between DRP1 and PGAM5.
Mitochondrial morphology and function are tightly linked. The
IMM is intricately structured and contains functionally distinct
regions, such as inner boundary regions that are close to OMM,
cristae invaginations and cristae junctions48–51. Formation of
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Fig. 7 Multimerization of full-length PGAM5 promotes clustered mitochondrial morphology. a Representative confocal images of COS7 cells transiently
transfected with the wild type (WT) or mutant full-length myc-tagged PGAM5 constructs and immunostained for the OMM marker Tom20 with anti-
Tom20 antibody (green), PGAM5 with anti-myc antibody (red), and nucleic-stain DAPI (blue). All scale bars correspond to 15 µm. b Quantification of
mitochondrial phenotypes observed by confocal microscopy in COS7 cells transiently expressing PGAM5 variants as described in a, based on at least three
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inner membrane supercomplexes by IMM proteins, such as
adenine nucleotide translocator52, ATP synthase50,53 and multi-
protein Mitofilin complex (MitOS)54, is important for structural
organization of the functional domains within the IMM. Our data
demonstrate that PGAM5 resides primarily in the IMM and acts
independently of DRP1 to influence mitochondrial morphology,
suggesting that PGAM5 has an intrinsic ability to alter mito-
chondrial architecture. Furthermore, oligomerization, but not
activity, appeared crucial for this ability of PGAM5. Hence,
PGAM5 oligomerization within IMM may play a structural role
in the maintenance of the functional mitochondrial membrane
architecture.
Our finding that cleaved PGAM5 forms filaments composed of
dodecameric phosphatase rings both in vitro and in cells adds a
new dimension of complexity to PGAM5 signaling. Filaments did
not influence the catalytic rate of PGAM5 in vitro nor the ability
of full-length PGAM5 to influence mitochondrial morphology in
cells. However, cleaved PGAM5, which accumulates with time in
the cytosol, sensitizes cells to apoptosis through sequestration of
the negative regulator of apoptosis, the ubiquitin ligase XIAP9.
Other cytosolic effectors of death pathways form filamentous
structures that are essential for executing cell death programs,
including the caspase-8 associated death complex55, the caspase-1
containing inflammasomes47 and the RIP1/RIP3 necrosomes56.
PGAM5 filamentation could ensure highly processive or coop-
erative dephosphorylation in these processes. We found that
cytosolic PGAM5 filaments colocalized with microtubules and
only formed when microtubules are intact. This phenomenon
ba
Tom20Myc-PGAM5 Overlay
W
T 
PG
AM
5 
F2
44
E 
PG
AM
5 
d
Un
tra
ns
fe
ct
ed
W
T 
PG
AM
5 
F2
44
E 
PG
AM
5 
Myc-PGAM5 Overlay
Tom20
W
T 
PG
AM
5 
F2
44
E 
PG
AM
5 
Tom20 Myc-PGAM5 Overlay
Tim23 Myc-PGAM5 Overlay
W
T 
PG
AM
5 
F2
44
E 
PG
AM
5 
Tom20
Myc
Tom20
Myc
Tim23
Myc
Tim23
Myc
WT PGAM5 
Tim23
Tim23
c
Fig. 8 PGAM5 localizes at inner mitochondrial membrane and at the membrane contact sites. a–d STED images of COS7 cells that were either
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may relate to the link between PGAM5 and the stability of the
Miro2 GTPase, which involves KEAP1 and the formation of a
ternary complex with the Nrf2 transcription factor, to control
stress-induced retrograde trafficking of mitochondria35. It is also
possible that PGAM5 filaments formed upon PGAM5 cleavage
reside primarily inside the mitochondria, playing yet unknown
role(s).
Although we still know little about the regulation of PGAM5
activity, the enhanced phosphatase activity in oligomerization-
competent PGAM5 supports the need for tight regulation of
PGAM5's oligomeric transitions. How binding partners or post-
translational modifications regulate PGAM5 catalytic activity
and/or oligomerization is a topic of future studies. An exciting
possibility is the pharmacological regulation of PGAM5 signaling
through regulation of the interaction between the MM and the
phosphatase domain. Compounds mimicking this binding event
could be of potential therapeutic interest in the treatment of
stroke, myocardial infarction, and other diseases by stimulating
the mitophagy-promoting functions of PGAM5.
Methods
Protein expression and purification. Wild-type full-length PGAM5 cDNA (cor-
responding to the PGAM5 long isoform (PGAM5L), residues 1–289) was purchased
from Addgene. For bacterial expression and purification, the Δ90 PGAM5 (residues
91–289) and Δ48 PGAM5 (residues 49–289) were cloned into the pET28a expression
vector (Novagen). These constructs were N-terminally tagged with hexahistidine (6×
-HIS) followed by a linker sequence encoding a TEV protease cleavage site
(ENLYFQS). Full-length and Δ23 (residues 24–289) PGAM5 variants for mammalian
cell expression and imaging were cloned into the pcDNA3.1+ vector (Invitrogen).
These constructs contained an internal myc-tag (EQKLISEEDL) inserted between
residue 42 and 43 of the PGAM5 sequence. Mutations were introduced using either
QuickChange mutagenesis or through Gibson assembly57. Primers used for muta-
genesis are as follows: H105A (Forward: 5′-acatcttcctcatcagggcttcccagtaccacgtgg-3′
Reverse: 5′-ccacgtggtactgggaagccctgatgaggaagatgt-3′), Y198E (F: 5′-gctccgtcttcctcatact
gcacagcttccggc-3′ R: 5′-gccggaagctgtgcagtatgaggaagacggagc-3′), R65A (F: 5′-agagacag
tggttctgccctgtcccagttggg-3′ R: 5′-cccaactgggacagggcagaaccactgtctct-3′), F244E (F: 5′-gc
cagccttcaggaggctcctgcagtgctctgcac-3′ R: 5′-gtgcagagcactgcaggagcctcctgaaggctggc-3′),
R288E (F: 5′-cctcccgacaagatcactgaatcctgagatccgaattc-3′ R: 5′-gaattcggatctcaggattcagt-
gatcttgtcgggagg-3′). Mutation of WT A4 was done by sequential mutation of W58A
and D59A and followed by W62A and D63A. W58A/D59A (F: 5′- gtcccagttgggggc
cgcgacaccggggccc-3′ R: 5′-gggccccggtgtcgcggcccccaactgggac-3′), W62A/D63A (F: 5′-g
tggttctcgcctggccgcgttggggtcccaga-3′ R: 5′-tctgggaccccaacgcggccaggcgagaaccac-3′).
Y92A (F: 5′-cgtggccttggctttggcgtggtccagcttggac-3′ R: 5′-gtccaagctggaccacgccaaa
gccaaggccacg-3′), D111A (F: 5′-cccagtaccacgtggccggctccctggagaag-3′ R: 5′-cttctcca
gggagccggccacgtggtactggg-3′), K191A (F: 5′-tgcacagcttccggcgcccaatgagacacggg-3′
R: 5′-cccgtgtctcattgggcgccggaagctgtgca-3′), R218A/E220A (F: 5′-gtaactgtcctccgcctgc
gcggc-0= atctgcgcgg-3′ R: 5′-ccgcgcagatgccgcgcaggcggaggacagttac-3′).
For recombinant protein expression, BL21 DE3 pLysS Escherichia coli cells
transformed with pET28a-PGAM5 constructs were cultured in Luria Broth media
supplemented with kanamycin (30 µg/mL) at 37 °C until 0.4 optical density at 600
nm was reached. Protein expression was induced with 0.2 mM IPTG and cells were
cultured for additional 12 h at 25 °C. Following collection by centrifugation at
5000×g, cell pellets were resuspended in Lysis Buffer (20 mM Tris-Cl pH 8.0, 500
mM NaCl, 0.5 mM TCEP, 5% glycerol, 20 mM Imidazole pH 8.0 supplemented
with EDTA-free protease inhibitors (Roche)). Cells were lysed by sonication at 25%
of max power in cycles of 4 s on and 2 s off for 5 min. Lysates were clarified by
centrifugation at 18,000×g and loaded by gravity flow on HiTrap Ni-NTA resin
(GE Healthcare). Protein was eluted using Elution Buffer (20 mM Tris-Cl pH 8.0,
500 mM NaCl, 0.5 mM TCEP, 5% glycerol, 200 mM Imidazole pH 8.0) and
exchanged into buffer containing 20 mM Tris-Cl pH 8.0, 150 mM NaCl, and 0.5
mM TCEP using a 10 kDa cutoff concentrator (Millipore). The sample was further
purified by SEC using a Superose 6 10/300 GL Increase column (GE Healthcare)
equilibrated in buffer containing 20 mM Tris-Cl pH 8.0, 150 mM NaCl and 0.5 mM
TCEP. Salt titration experiments were performed by SEC in buffer conditions
containing 20 mM Tris-Cl pH 8.0, 0.5 mM TCEP and concentrations of NaCl
ranging from 150 mM to 1M.
Peptides. The ASK1 phosphopeptide (NFEDH(pS)APPSP) and the PGAM5 MM
peptide (GPGVWDPNWDRREP)33, were purchased at a purity of 95% or greater
(Elim Biopharma). Peptides were resuspended in 20 mM Tris-Cl pH 7.5, aliquoted,
and flash frozen in liquid nitrogen prior to storage at −80 °C.
Negative-stain sample preparation and data acquisition. Homemade grids were
prepared for negative-stain experiments by depositing a thin plastic layer on the
surface of 400-mesh copper grids (Ted Pella) floated on 2% amyl acetate (EMS)58.
Air-dried grids were then coated with ~3 nm of continuous carbon film, negative
glow discharged, and loaded with 2.5 µL of purified PGAM5 (~0.01–0.1 mg/mL).
Following a 30 s incubation, grids were briefly dipped in two drops of sample buffer
and one drop of 0.75% uranyl formate staining solution with blotting performed
between drops by touching the edge of the grid briefly to the surface of Whatman 1
filter paper. Sample grids were dipped in a second drop of stain for 30 s, blotted on
filter paper, and air dried prior to imaging. Images were collected using a 120 kV
Tecnai T12 (FEI) microscope equipped with a Gatan 4× 4 K CCD camera at 52 K
magnification corresponding to a pixel size of 2.21 Å.
Cryo-EM sample preparation, data acquisition, and processing. For cryo-EM
experiments, we first screened grid type and protein buffer to identify optimal
conditions for data collection. We observed significant orientation bias as well as
aggregation on traditional Quantifoil 1.2/1.3 400-mesh spacing gold grids (Electron
Microscopy Sciences) that could not be improved by changes in buffer conditions
(i.e., varying salt concentration, addition of glycerol, addition of low concentrations
of detergent). While aggregation was somewhat alleviated by sample application on
C-flat 1.2/1.3 holey thick carbon grids (Electron Microscopy Sciences), sample
quality appeared to be the best for 3 μL of purified PGAM5 sample (at 0.10 mg/mL)
in ring stabilization buffer (20 mM Tris-Cl pH 8.0, 600 mM NaCl, 0.5 mM TCEP)
applied to freshly glow-discharged Lacey Formvar/Carbon 400-mesh continuous
carbon coated copper grids (Ted Pella) placed inside a Vitrobot Mark IV (FEI)
equilibrated to 4 °C and 100% humidity. Following a 10 s incubation, grids were
blotted between Whatman 1 paper for 6 s, and plunge-frozen in liquid ethane.
Images were recorded using a 300 kV Titan Krios microscope (FEI) equipped with
a K2 Summit detector (Gatan) operated in super-resolution mode (UC Berkeley).
Totally, 6543 images were collected at a nominal magnification of 22.5 K, corre-
sponding to a pixel size of 0.53 Å. Dose-fractionated movies were acquired at an
electron flux of 1.8 e−1/A2 over 7.75 s with 0.25 s exposures per frame (31 frames
total), corresponding to a total dose of 55 e−1/Å2. Images were recorded with a
defocus range of −1 to 2.5 μm.
Frame-based motion correction, 2× binning, and dose weighting were
performed on dose-fractionated image stacks using MotionCor259 resulting in one
integrated image per stack with a pixel size of 1.07 Å. The contrast transfer function
was estimated from motion corrected, nondose-weighted images using GCTF
version 1.0660. From an initial subset of micrographs, approximately 1000 particles
were manually picked and subject to likelihood-based 2D classification in Relion
2.061 to generate templates for automated particle selection using Gautomatch
version 0.5560. In total, 131,396 particles were extracted at a box size of 190 pixels
with 2.14 Å/pixel and subject to 2D classification to eliminate particles of poor
quality resulting in a dataset of 22,422 particles corresponding to orientations in
which C6 symmetry of the dodecameric assembly of Δ48 PGAM5 was observed.
The final selected particles were re-centered and re-extracted at full pixel size to
generate the class average shown in Fig. 2a. Data collection details are reported in
Supplementary Table 1.
X-ray crystallography. The Δ90 H105A PGAM5 construct was crystallized using
hanging drop vapor diffusion at room temperature in the presence of the ASK1
phosphopeptide alone or together with the MM peptide. The electron density
corresponding to the ASK1 peptide could not be resolved in any of the structures.
For crystallization of Δ90 H105A PGAM5 with the ASK1 peptide, protein was
concentrated to 5 mg/mL and incubated with the peptide on ice at a 5:1 molar ratio
of peptide:protein. Crystals were grown in a 2 μL drop (1 μL protein+ 1 μL
reservoir solution) against a reservoir solution comprised of 100 mM HEPES pH
7.5, 200 mM MgCl2 and 30% w/v PEG 400. For crystallization of the Δ90 H105A
PGAM5 in complex with the MM peptide, protein at a concentration of 7.5 mg/mL
was incubated on ice with 3:3:1 molar ratio of ASK1 peptide:MM peptide:protein.
Crystals were grown in 2 μL drops (1 μL protein+ 1 μL reservoir solution) equi-
librated against reservoir solution containing 100 mM Tris-Cl pH 7.0, 200 mM
MgCl2 and 10% w/v PEG 8000. Crystals from both conditions were cryoprotected
with Paratone-N oil and flash-cooled to 100 K in liquid nitrogen.
X-ray diffraction data were collected at 1.111 Å, 77 K at the ALS 8.3.1. beamline
(Berkeley, CA) on a Pilatus 6M detector. Data were indexed with XDS62, scaled in
Aimless63 and phases determined in Phaser64. Δ90 PGAM5 H105A crystals
diffracted to 1.7 Å in space group P212121 and with unit cell dimensions: a= 71.0
Å, b= 72.0 Å, c= 81.9 Å, α= β= γ= 90° and with two molecules in the
asymmetric unit. A solution was generated by molecular replacement using one
copy of PDB 3MXO as the search model. Crystals of Δ90 PGAM5 H105A/MM
diffracted to 2.6 Å in the space group P212121 with unit cell dimensions: a= 49.3 Å,
b= 242.5 Å, c= 272.5 Å, α= β= γ= 90° and with twelve molecules in the
asymmetric unit. The structure was solved by molecular replacement using a single
monomer of PDB 5MUF and searching for 12 copies in the asymmetric unit.
Refinement was performed in Phenix65 with iterative rounds of model building in
Coot66. Model quality was assessed with MolProbity67 and coordinates deposited
in the RCSB PDB databank under the PDB codes 6CNI (Δ90 PGAM5 H105A) and
6CNL (Δ90 PGAM5 H105A/MM). Detailed statistics for data collection and
structure refinement are reported in Table 1.
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Phosphatase activity assay. Phosphatase assays were performed at room tem-
perature for wild type and mutant constructs of 6xHIS-Δ48 PGAM5 (A4, R65A,
H105A, Y198E, F244E, R269E, and R288E). ASK1 phosphopeptide was serially
diluted (0–200 µM) into reaction buffer (20 mM Tris-Cl pH 8.0, 150 mM NaCl and
0.5 mM TCEP) and the assay was started by the addition of PGAM5 (20 nM). The
reaction was quenched at various time points with the addition of malachite green
(Promega) and the total free phosphate in solution measured as the absorbance at
620 nm. Initial rates and Michaelis–Menten kinetic parameters were calculated in
Prism (GraphPad) and are reported in Table 2.
Subcellular fractionation. HEK293T cells (ATCC) cultured under normal con-
ditions were treated with CCCP (50 µM) (Carbonyl cyanide 3-chlorophenylhy-
drazone, Sigma Aldrich) prepared in complete media for 4 h prior to harvest.
Following treatment, subcellular fractionation of cellular cytoplasm and mito-
chondria was performed by resuspending harvested cells first with plasma mem-
brane (PM) permeabilization buffer (20 mM HEPES, 100 mM Sucrose, 2.5 mM
MgCl2, 100 mM KCl, 10 mM DTT, 0.025% digitonin, pH 7.4) supplemented with
DNase (Roche) and complete protease inhibitors without EDTA (Roche). Fol-
lowing incubation at 4 °C for 30 min with end over end mixing, membrane frac-
tions were separated from cytosol by centrifugation at 4 °C and 13,000×g for 10
min. Supernatant was collected as the cytosolic (cyto) fraction. The remaining
pellet was washed twice by resuspending in cold PBS and centrifugation at 4 °C and
600×g for 5 min in between washes. Resuspended mitochondrial membranes were
then solubilized in a volume of mitochondrial permeabilization buffer (20 mM
Bis–Tris, 50 mM NaCl, 10% glycerol, 10 mM DTT, 2% digitonin, pH 7.4, supple-
mented with protease inhibitors) equivalent to the volume of PM buffer used and
incubated with end over end mixing for 30 min at 4 °C prior to one final cen-
trifugation at 4 °C and 13,000×g for 10 min. Supernatant from this fraction was
collected as the mitochondrial (mito) fraction. Samples were prepared for sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) loading controls
and BN-PAGE by adding equivalent volumes of either standard SDS-PAGE
loading dye or 10× BN-PAGE loading dye (100 mM Bis–Tris pH 7.0, 500 mM 6-
amino-nexamoic acid, and 5% Coomassie Blue R-250), respectively. Samples for
SDS-PAGE were normalized for concentration and subject to immunoblotting with
antibodies against PGAM5 (1:3000) (kind gift from Z. Wang), β-tubulin (1:2000)
(Cell Signaling Technologies, Inc., 2128S), and Tom20 (1:100) (Santa Cruz Bio-
technologies, Inc., sc-17764). Uncropped scans of blots shown in Fig. 6a are
included in Supplementary Figure 6.
Blue Native-PAGE. BN-PAGE was performed for equivalent volumes of the total
fractionation sample supplemented with BN-PAGE loading dye68,69. Samples were
loaded onto a 4–16% Native-PAGE gel (Invitrogen) and electrophoresed under 8
mA of constant current in blue cathode buffer (Invitrogen) until the dye front had
migrated approximately one-third of the way through the resolving gel. Next, the
blue cathode buffer was replaced with clear anode buffer (Invitrogen) and elec-
trophoresis continued at 150 V for 60 min, then increased to 250 V for the
remainder of the experiment (45 min). Prior to transfer to polyvinylidene fluoride
(PVDF) (Millipore) and immunoblotting, the native gels was soaked for 10 min in
tris-glycine transfer buffer supplemented with 20% methanol and 0.05% SDS.
Following the transfer, the PVDF membrane was completely destained in 100%
methanol, then equilibrated in blocking buffer (5% w/v milk prepared in TBST
buffer) prior to immunoblotting with anti-PGAM5 antibody.
Confocal imaging. Monkey kidney COS7 cells (obtained from J. Kuriyan, UC
Berkeley) were cultured at 37 °C in 5% CO2 with DMEM supplemented with 10%
fetal bovine serum (FBS), and 1% penicillin–streptomycin (Thermo Fisher). Mouse
embryonic fibroblasts (obtained from D. Chan, Caltech) were cultured at 37 °C in
5% CO2 with DMEM supplemented with 10% FBS, 100 μM nonessential amino
acids and 1% penicillin–streptomycin (Thermo Fisher). For imaging, COS7 and
MEF cells were plated at a density of 0.9 × 105 cells per well in a six-well plate
(Corning) on acid-washed glass coverslips and grown for 16 h at 37 °C. Cells were
then transfected with 500 ng of full-length or cleaved (Δ23) PGAM5 using Lipo-
fectamine 3000 (Invitrogen) and incubated for 24 h at 37 °C. For nocodazole
treatments, relevant cells were incubated with 10 μM nocodazole in media for 45
min at 37 °C. Following transfection and drug treatment, cells were washed with
cold PBS, and fixed with 3.7% formaldehyde for 1 h at room temperature. After
three rinses with PBS, cells were permeabilized with 0.1% Triton X-100 for 5 min,
then washed three times with PBS. Permeabilized cells were incubated with the
blocking buffer (1% BSA in PBS) for 5 min at room temperature, then for 1 h at 37
°C with blocking buffer supplemented with primary antibodies. Those included
anti-myc (mouse, 1:6000 dilution in blocking buffer) (Millipore, 05-724), anti-
Tom20 (rabbit, 1:250) (Santa Cruz Biotechnology, sc-17764), anti-β-tubulin (rab-
bit, 1:25) (Cell Signaling Technologies, 2128S), anti-β-tubulin (rabbit, 1:250)
(Abcam, Ab179513), or Alexa Fluor-647 Phalloidin (1:20) (Thermo Fischer,
A22287). For Tim23 labeling, blocking buffer contained 10% FBS and primary
labeling used Anti-Tim23 antibody (rabbit, 1:250) (Proteintech, 11123-1-AP).
Coverslips were washed three times with PBS and incubated with respective sec-
ondary antibodies: FITC-488 (rabbit, 1:500) (Invitrogen, A-11034) and Alexa-647
(mouse, 1:500) (Invitrogen, A327728) for 1 h at 37 °C in the dark. Following three
washes with PBS, samples were incubated with the nuclei stain DAPI (1:1000
dilution in water) (Thermo Fischer, D1306) for 5 min at room temperature. Fol-
lowing three final water washes to remove excess DAPI, coverslips were mounted
using ProLong Gold (Invitrogen) and dried overnight at room temperature in the
dark. Imaging was done using a Nikon TIRF microscope with a Yokagawa CSU-X1
spinning disk confocal consisting of 405, 491, 561 and 640 nm lasers with the use of
a 60x objective. Data were processed using FIJI v1.0 (55).
Structure illumination imaging. COS7 cells for SIM imaging were cultured,
transfected, and prepared for imaging as for confocal microscopy. Slides were
imaged on an N-SIM (OMX microscope with 405, 488, 561, and 640 nm lasers)
using an Apo TIRF 100× objective with 1.56 oil in 3D mode and standard oper-
ating procedure. Image reconstruction was performed in SoftWoRx v6.5.2 (GE
Healthcare).
STED imaging. COS7 cells for STED imaging were cultured, transfected, and
prepared for imaging as for confocal and SIM microscopy, however, using different
secondary antibodies: secondary Alexa-594 (rabbit, 1:500) (Invitrogen, R37117)
and Alexa-647 (mouse, 1:500) (Invitrogen) antibodies. Images were acquired using
a Leica STED SP8 microscope (equipped with a white light laser, a 775 nm
depletion laser and 100× objective HC PL APO 100×/1.40 OIL) using standard
operating procedure. Images were processed in FIJI v1.070.
Reporting Summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this Article.
Data availability
Coordinates have been deposited in the Protein Data Bank with the accession
number 6CNI (Δ90 PGAM5 H105A) and 6CNL (Δ90 PGAM5 H105A/MM). Data
supporting the findings of this manuscript are available from the corresponding
author upon reasonable request.
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